KRAS peptide vaccine

Phase 1Vaccine

SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

KRAS peptide vaccine is one of 49 small molecule programs targeting Colorectal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

24 2

Adrucil

EElorac, Inc.

Phase 3

87 3

Tecentriq

Roche

Phase 3

6 4

Decadron

AAspen Global Incorporated

Phase 3

7 5

Botensilimab

AAgenus Inc.

Phase 3

10 6

Zanzalintinib

Merck & Co.

Phase 3

1 7

XL092

Roche

Phase 3

1 8

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

2 9

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 3

2 10

Calcium Levofolinate

FFujian Cancer Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Colorectal Cancer

NCT04117087

Q4 2030

Phase 1Recruiting

Colorectal Cancer

NCT06411691

Clinical

Trials by Indication[1]

Colorectal Cancer2 trials

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Adenocarcinoma

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT06411691·54 enrolled

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT04117087·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for KRAS peptide vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KRAS peptide vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KRAS peptide vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

KRAS peptide vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2030

Trials by Indication[1]

Colorectal Cancer2 trials

References

Drug Info

Quick Facts

Related News